Antisense oligonucleotides (ASOs) are short oligonucleotides that can modify gene expression and mRNA splicing in the nervous system. The FDA has approved ASOs for treatment of ten genetic disorders, with many applications currently in the pipeline. We describe the molecular mechanisms of ASO treatment for four neurodevelopmental and neuromuscular disorders. The ASO nusinersen is a general treatment for mutations of SMN1 in spinal muscular atrophy that corrects the splicing defect in the SMN2 gene. Milasen is a patient-specific ASO that rescues splicing of CNL7 in Batten’s disease. STK-001 is an ASO that increases expression of the sodium channel gene SCN1A by exclusion of a poison exon. An ASO that reduces the abundance of the SCN8A mRNA is therapeutic in mouse models of developmental and epileptic encephalopathy. These examples demonstrate the variety of mechanisms and range of applications of ASOs for treatment of neurodevelopmental disorders.

1.
Corey
DR
.
Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy
.
Nat Neurosci
.
Apr 2017
;
20
(
4
):
497
9
. .
2.
Kim
J
,
Hu
C
,
Moufawad El Achkar
C
,
Black
LE
,
Douville
J
,
Larson
A
,
Patient-customized oligonucleotide therapy for a rare genetic disease
.
N Engl J Med
.
2019
;
381
(
17
):
1644
52
. .
3.
Carroll
JB
,
Warby
SC
,
Southwell
AL
,
Doty
CN
,
Greenlee
S
,
Skotte
N
,
Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant Huntingtin
.
Mol Ther
.
Dec 2011
;
19
(
12
):
2178
85
. .
4.
Monia
BP
,
Lesnik
EA
,
Gonzalez
C
,
Lima
WF
,
McGee
D
,
Guinosso
CJ
,
Evaluation of 2′-modified oligonucleotides containing 2′-deoxy gaps as antisense inhibitors of gene expression
.
J Biol Chem
.
1993
;
268
(
19
):
14514
22
. .
5.
McKay
RA
,
Miraglia
LJ
,
Cummins
LL
,
Owens
SR
,
Sasmor
H
,
Dean
NM
.
Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-alpha expression
.
J Biol Chem
.
Jan 1999
;
274
(
3
):
1715
22
. .
6.
Khvorova
A
,
Watts
JK
.
The chemical evolution of oligonucleotide therapies of clinical utility
.
Nat Biotechnol
.
Mar 2017
;
35
(
3
):
238
48
. .
7.
Shen
W
,
De Hoyos
CL
,
Migawa
MT
,
Vickers
TA
,
Sun
H
,
Low
A
,
Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index
.
Nat Biotechnol
.
Jun 2019
;
37
(
6
):
640
50
. .
8.
Kolb
SJ
,
Kissel
JT
.
Spinal muscular atrophy: a timely review
.
Arch Neurol
.
Aug 2011
;
68
(
8
):
979
. .
9.
Crawford
TO
,
Pardo
CA
.
The neurobiology of childhood spinal muscular atrophy
.
Neurobiol Dis
.
Apr 1996
;
3
(
2
):
97
110
. .
10.
Zerres
K
,
Rudnik-Schöneborn
S
,
Forrest
E
,
Lusakowska
A
,
Borkowska
J
,
Hausmanowa-Petrusewicz
I
.
A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and III SMA): 569 patients
.
J Neurol Sci
.
Feb 1997
;
146
(
1
):
67
72
. .
11.
Coovert
DD
,
Le
TT
,
McAndrew
PE
,
Strasswimmer
J
,
Crawford
TO
,
Mendell
JR
,
The survival motor neuron protein in spinal muscular atrophy
.
Hum Mol Genet
.
Aug 1997
;
6
(
8
):
1205
14
. .
12.
Lefebvre
S
,
Bürglen
L
,
Reboullet
S
,
Clermont
O
,
Burlet
P
,
Viollet
L
,
Identification and characterization of a spinal muscular atrophy-determining gene
.
Cell
.
Jan 1995
;
80
(
1
):
155
65
. .
13.
Rigo
F
,
Chun
SJ
,
Norris
DA
,
Hung
G
,
Lee
S
,
Matson
J
,
Pharmacology of a central nervous system delivered 2′-O-methoxyethyl-modified survival of motor neuron splicing oligonucleotide in mice and nonhuman primates
.
J Pharmacol Exp Ther
.
Jul 2014
;
350
(
1
):
46
55
. .
14.
Hua
Y
,
Sahashi
K
,
Hung
G
,
Rigo
F
,
Passini
MA
,
Bennett
CF
,
Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model
.
Genes Dev
.
Aug 2010
;
24
(
15
):
1634
44
. .
15.
Passini
MA
,
Bu
J
,
Richards
AM
,
Kinnecom
C
,
Sardi
SP
,
Stanek
LM
,
Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy
.
Sci Transl Med
.
Mar 2011
;
3
(
72
):
72ra18
. .
16.
Hoot
NR
.
“Nusinersen for type 1 spinal muscular atrophy: a father’s perspective
.
Pediatrics
.
Oct 2019
;
144
(
4
):
e20190226
.
17.
Chiriboga
CA
,
Swoboda
KJ
,
Darras
BT
,
Iannaccone
ST
,
Montes
J
,
De Vivo
DC
,
Results from a phase 1 study of nusinersen (ISIS-SMN Rx ) in children with spinal muscular atrophy
.
Neurology
.
Mar 2016
;
86
(
10
):
890
7
.
18.
Finkel
RS
,
Chiriboga
CA
,
Vajsar
J
,
Day
JW
,
Montes
J
,
De Vivo
DC
,
Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study
.
Lancet
.
2016
;
388
(
10063
):
3017
26
. .
19.
Osredkar
D
,
Jílková
M
,
Butenko
T
,
Loboda
T
,
Golli
T
,
Fuchsová
P
,
Children and young adults with spinal muscular atrophy treated with nusinersen
.
Eur J Paediatric Neurol
.
Jan 2021
;
30
(
4
):
1
8
. .
20.
Mendell
JR
,
Al-Zaidy
S
,
Shell
R
,
Arnold
WD
,
Rodino-Klapac
LR
,
Prior
TW
,
Single-dose gene-replacement therapy for spinal muscular atrophy
.
N Engl J Med
.
Nov 2017
;
377
(
18
):
1713
22
. .
21.
Lim
KH
,
Han
Z
,
Jeon
HY
,
Kach
J
,
Jing
E
,
Weyn-Vanhentenryck
S
,
Antisense oligonucleotide modulation of non-productive alternative splicing upregulates gene expression
.
Nat Commun
.
Dec 2020
;
11
(
1
):
3501
. .
22.
Han
Z
,
Chen
C
,
Christiansen
A
,
Ji
S
,
Lin
Q
,
Anumonwo
C
,
Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model of Dravet syndrome
.
Sci Transl Med
.
Aug 2020
;
12
(
558
):
eaaz6100
. .
23.
Larsen
J
,
Carvill
GL
,
Gardella
E
,
Kluger
G
,
Schmiedel
G
,
Barisic
N
,
The phenotypic spectrum of SCN8A encephalopathy
.
Neurology
.
Feb 2015
;
84
(
5
):
480
9
. .
24.
Meisler
MH
.
SCN8A encephalopathy: mechanisms and models
.
Epilepsia
.
Dec 2019
;
60
(
S3
):
S86
91
.
25.
Meisler
MH
,
Helman
G
,
Hammer
MF
,
Fureman
BE
,
Gaillard
WD
,
Goldin
AL
,
SCN8A encephalopathy: research progress and prospects
.
Epilepsia
.
Jul 2016
;
57
(
7
):
1027
35
. .
26.
Lenk
GM
,
Jafar-Nejad
P
,
Hill
SF
,
Huffman
LD
,
Smolen
CE
,
Wagnon
JL
,
Scn8a antisense oligonucleotide is protective in mouse models of SCN8A encephalopathy and Dravet Syndrome
.
Ann Neurol
.
2020
;
87
(
3
):
339
46
. .
27.
Meisler
MH
,
Hill
SF
,
Yu
W
.
Sodium channelopathies in neurodevelopmental disorders
.
Nat Rev Neurosci
.
2021
;
22
(
3
):
152
66
.
28.
Ogiwara
I
,
Miyamoto
H
,
Morita
N
,
Atapour
N
,
Mazaki
E
,
Inoue
I
,
Nav1.1 localizes to axons of Parvalbumin-positive inhibitory interneurons: a circuit basis for epileptic seizures in mice carrying an Scn1a gene mutation
.
J Neurosci
.
May 2007
;
27
(
22
):
5903
14
. .
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.